Long-term study on discontinuation rate, resolution/remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia

INTERVENTION: Aripiprazole group (maximum of 104 weeks) Blonanserin group (maximum of 104 weeks) Paliperidone group (maximum of 104 weeks) CONDITION: Schizophrenia PRIMARY OUTCOME: ‐ Discontinuation rate SECONDARY OUTCOME: ‐ Resolution/remission ; ‐ Social functioning rate (change in PSP and EQ‐5D sores); ‐ Improvement and worsening/recurrence of psychiatric symptoms; ‐ Safety (adverse events, DIEPSS) INCLUSION CRITERIA: The subjects will be patients meeting all of the following criteria. ‐ Out‐patients 20 years of age or older at the time informed consent is obtained ‐ Patients with schizophrenia meeting the DSM‐IV‐TR diagnostic criteria ‐ Patients who require treatment with an antipsychotic medication, or patients who need to switch their current antipsychotic medication because the treatment is ineffective or poorly tolerated, or for some other reason ‐ Patients who personally give written informed consent to participate in the study